探讨HE4、CEA、ProGRP、CYFRA21-1以及NSE联合检测在肺癌诊断中的应用

On Application of Combined Detection of HE4,CEA,ProGRP,CYFRA21—1 and NSE in the Diagnosis of Lung Cancer

目的探讨人附睾蛋白4(HE4)、癌胚抗原(CEA)、胃泌素释放肽前体(ProGRP)、细胞角蛋白19片段(CYFRA21-1)以及神经元特异性烯醇化酶(NSE)联合检测在肺癌诊断中的应用价值。方法选择肺癌患者104例,肺炎患者62例,健康体检者75例。采用化学发光法检测血清样本中HE4、ProGRP、CEA、CYFRA21-1以及NSE的水平,进行统计分析以观察各类指标在肺癌诊断中的敏感性和特异性。结果肺癌组血清HE4、CEA、ProGRP、NSE和CYFRA21-1水平显著高于肺炎组和健康体检组,差异有统计学意义(P<0.05)。肺炎组NSE水平略高于健康对照组,差异有统计学意义(P<0.05);肺炎组其它四种肿瘤标志物血清水平与健康对照组无统计学差异(P>0.05)o联合检测五种肿瘤标志物敏感性和特异性为82%和74%o结论组合检测HE4、CEA、ProGRP、NSE和CYFRA21-1可以提高肺癌临床诊断效能,有利于肺癌患者的治疗和预后。

Objective To explore the application value of combined detection of human epididymis protein 4(HE4), carcinoembryonic antigen(CEA), gastrin releasing peptide precursor(Pro-GRP), cytokeratin 19 fragment(CYFRA21-1) and neuron-specific enolase(NSE) in the diagnosis of lung cancer. Methods 104 patients with lung cancer, 62 patients with pneumonia, and 75 healthy patients were selected. The expression levels of HE4, ProGRP, CEA, CYFRA21-1 and NSE in serum samples were detected by chemiluminescence method,and then statistical analysis was conducted to observe the sensitivity and specificity of various indicators in the diagnosis of lung cancer. Results: The levels of serum HE4, CEA, ProGRP, NSE and CYFRA21-1 in the lung cancer group were significantly higher than those in the healthy physical examination group and pneumonia group, and the difference was statistically significant(P<0.05). The NSE level of the pneumonia group was slightly higher than that of the healthy control group, the difference was statistically significant(P<0.05). The serum levels of the other four tumor markers in the pneumonia group were not statistically different from the healthy control group(P>0.05). The sensitivity and specificity of the joint detection of five tumor markers were 82% and74%. Conclusion: The combined detection of HE4, CEA, ProGRP, NSE and CYFRA21-1 can improve the clinical diagnosis efficiency of lung cancer and is beneficial to the treatment and prognosis of lung cancer patients.